The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab.
Mallardo D, Woodford R, Menzies AM, Zimmer L, Williamson A, Ramelyte E, Dimitriou F, Wicky A, Wallace R, Mallardo M, Cortellini A, Budillon A, Atkinson V, Sandhu S, Olivier M, Dummer R, Lorigan P, Schadendorf D, Long GV, Simeone E, Ascierto PA.
Mallardo D, et al.
J Transl Med. 2023 Oct 25;21(1):753. doi: 10.1186/s12967-023-04607-4.
J Transl Med. 2023.
PMID: 37880788
Free PMC article.
The patients whose glucose blood level increased after 3 months of treatment with nivolumab + relatinib compared to baseline (ratio of blood level at baseline/after 3 months > 1.5) had a worse prognosis than those whose glucose level had not increased. This result was o …
The patients whose glucose blood level increased after 3 months of treatment with nivolumab + relatinib compared to baseline (ratio of blood …